Document Detail


An open, nonrandomized, comparative study of imiquimod 5% cream versus 10% potassium hydroxide solution in the treatment of molluscum contagiosum.
MedLine Citation:
PMID:  19171985     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: There are numerous therapeutic modalities available for treatment of molluscum contagiosum. However, the ablative modalities are painful and not suitable for children. AIM: We aimed to evaluate and compare the safety and efficacy of 2 of the painless modalities, viz., 5% imiquimod cream and 10% potassium hydroxide (KOH) solution, in the treatment of molluscum contagiosum. METHODS: Out of a total of 40 patients of molluscum contagiosum in the study, 18 patients in the imiquimod group and 19 patients in the KOH group completed the study. The given medication was applied by the patient or a parent to mollusca at night, 3 days per week. Imiquimod was continued till clinical cure; and 10% KOH, till lesions showed signs of inflammation. Assessments of response and side effects were performed at the end of week 4, week 8, and week 12. Significance was tested by Student's t test and Mann-Whitney test. RESULTS: The mean lesion count decreased from 22.39 to 10.75 with imiquimod and from 20.79 to 4.31 with KOH at the end of 12 weeks. We found complete clearance of lesions in 8 (44%) patients with imiquimod and in 8 (42.1%) patients with 10% KOH. Minor side effects were seen in 15 (78.9%) patients on KOH and 10 (55.5%) patients on imiquimod. CONCLUSIONS: The results of this study suggest that both 5% imiquimod cream and 10% KOH solution are equally effective in molluscum contagiosum though KOH has a faster onset of action. However, KOH solution is associated with a higher incidence of side effects.
Authors:
Amol Metkar; Sushil Pande; Uday Khopkar
Related Documents :
15492435 - Topical imiquimod 5% cream in external anogenital warts: a randomized, double-blind, pl...
9018085 - Effects of topical treatment with fenretinide (4-hpr) and plasma vitamin a levels in pa...
14732655 - Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal ...
10052405 - Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial.
21179335 - Changes in sexual function after the midurethral sling procedure for stress urinary inc...
19899935 - Viral kinetics during the first month of treatment in patients with genotype 1 chronic ...
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Indian journal of dermatology, venereology and leprology     Volume:  74     ISSN:  0973-3922     ISO Abbreviation:  Indian J Dermatol Venereol Leprol     Publication Date:    2008 Nov-Dec
Date Detail:
Created Date:  2009-01-27     Completed Date:  2009-11-16     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7701852     Medline TA:  Indian J Dermatol Venereol Leprol     Country:  India    
Other Details:
Languages:  eng     Pagination:  614-8     Citation Subset:  IM    
Affiliation:
Department of Dermatology, Seth GS Medical College and KEM Hospital, Mumbai, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Topical
Adolescent
Adult
Aminoquinolines / administration & dosage*,  adverse effects
Child
Child, Preschool
Female
Humans
Hydroxides / administration & dosage*,  adverse effects
Longitudinal Studies
Male
Molluscum Contagiosum / drug therapy*,  pathology
Pharmaceutical Solutions / administration & dosage
Pigmentation Disorders / chemically induced
Potassium Compounds / administration & dosage*,  adverse effects
Treatment Outcome
Young Adult
Chemical
Reg. No./Substance:
0/Aminoquinolines; 0/Hydroxides; 0/Pharmaceutical Solutions; 0/Potassium Compounds; 1310-58-3/potassium hydroxide; 99011-02-6/imiquimod

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  An uncontrolled, open label study of sulfasalazine in severe alopecia areata.
Next Document:  Immune reconstitution inflammatory syndrome.